Cue Biopharma annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Cue Biopharma Revenue Growth & History (CUE)
Cue Biopharma reported $27.5M in revenue for fiscal 2025, an increase of 195.75% from the previous fiscal year.
View full Cue Biopharma company overviewCue Biopharma annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $27.5M | $18.2M | +195.75% |
| 2024 | 2024-12-31 | $9.3M | $3.8M | +69.16% |
| 2023 | 2023-12-31 | $5.5M | $4.2M | +340.96% |
| 2022 | 2022-12-31 | $1.2M | −$13.7M | −91.67% |
| 2021 | 2021-12-31 | $14.9M | $11.8M | +373.68% |
| 2020 | 2020-12-31 | $3.2M | −$304,006 | −8.79% |
| 2019 | 2019-12-31 | $3.5M | $2.3M | +202.67% |
| 2018 | 2018-12-31 | $1.1M | — | — |
Cue Biopharma quarterly revenue
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.9M | $4.9M | +166.66% |
| Q1 2026 | 2026-03-31 | $5.7M | $5.3M | +1250.59% |
| Q4 2025 | 2025-12-31 | $21.9M | $20.4M | +1292.26% |
| Q3 2025 | 2025-09-30 | $2.1M | −$1.2M | −35.58% |
| Q2 2025 | 2025-06-30 | $3.0M | $296,000 | +11.14% |
| Q1 2025 | 2025-03-31 | $421,000 | −$1.3M | −75.48% |
| Q4 2024 | 2024-12-31 | $1.6M | −$245,000 | −13.45% |
| Q3 2024 | 2024-09-30 | $3.3M | $1.2M | +58.86% |
| Q2 2024 | 2024-06-30 | $2.7M | $1.3M | +92.33% |
| Q1 2024 | 2024-03-31 | $1.7M | $1.5M | +818.18% |
| Q4 2023 | 2023-12-31 | $1.8M | $1.7M | +1105.96% |
| Q3 2023 | 2023-09-30 | $2.1M | $2.0M | +2988.24% |
| Q2 2023 | 2023-06-30 | $1.4M | $1.4M | +5215.38% |
| Q1 2023 | 2023-03-31 | $187,000 | −$813,000 | −81.30% |
| Q4 2022 | 2022-12-31 | $151,000 | −$8.1M | −98.17% |
| Q3 2022 | 2022-09-30 | $68,000 | −$2.3M | −97.16% |
| Q2 2022 | 2022-06-30 | $26,000 | −$2.7M | −99.05% |
| Q1 2022 | 2022-03-31 | $1.0M | −$553,000 | −35.61% |
| Q4 2021 | 2021-12-31 | $8.3M | $7.8M | +1636.57% |
| Q3 2021 | 2021-09-30 | $2.4M | $1.7M | +240.20% |
| Q2 2021 | 2021-06-30 | $2.7M | $1.7M | +154.79% |
| Q1 2021 | 2021-03-31 | $1.6M | $653,000 | +72.56% |
| Q4 2020 | 2020-12-31 | $475,325 | −$574,006 | −54.70% |
| Q3 2020 | 2020-09-30 | $704,000 | −$280,000 | −28.46% |
| Q2 2020 | 2020-06-30 | $1.1M | $20,000 | +1.90% |
| Q1 2020 | 2020-03-31 | $900,000 | $530,000 | +143.24% |
| Q4 2019 | 2019-12-31 | $1.0M | — | — |
| Q3 2019 | 2019-09-30 | $984,000 | $535,000 | +119.15% |
| Q2 2019 | 2019-06-30 | $1.1M | $883,000 | +513.37% |
| Q1 2019 | 2019-03-31 | $370,000 | — | — |
| Q3 2018 | 2018-09-30 | $449,000 | — | — |
| Q2 2018 | 2018-06-30 | $172,000 | — | — |
Cue Biopharma revenue growth trends
Over the last five reported fiscal years, revenue grew from $3.2M to $27.5M, a compound annual growth rate of 54.16%. Cue Biopharma's latest reported quarter, Q2 2026, generated $7.9M in revenue, an increase of 166.66% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Cue Biopharma source filings ↗